NASDAQ:XOMAP XOMA (XOMAP) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free XOMAP Stock Alerts $25.02 -0.26 (-1.03%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$25.02▼$25.2850-Day Range$24.66▼$25.4352-Week Range$21.40▼$25.98Volume1,482 shsAverage Volume1,719 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.63%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get XOMA alerts: Email Address Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About XOMA Stock (NASDAQ:XOMAP)XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More XOMAP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XOMAP Stock News HeadlinesMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xoma with Enhanced Price Target Reflecting New Royalty Assets and Growth ProspectsMay 12, 2024 | americanbankingnews.comXOMA Co. (NASDAQ:XOMAP) Short Interest Down 28.6% in AprilApril 30, 2024 | msn.comLeerink Partners Initiates Coverage of XOMA (XOMA) with Outperform RecommendationApril 17, 2024 | thestreet.comXOMA Corporation 8.625% Series A Cumulative Perpetual Preferred StockMarch 21, 2024 | msn.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendMarch 13, 2024 | finanznachrichten.deAdhoc: Kuros Biosciences AG: Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023March 11, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xoma (XOMA) and Lexicon Pharmaceuticals (LXRX)February 23, 2024 | msn.comCox Communications wins order overturning $1 billion US copyright verdictFebruary 17, 2024 | finance.yahoo.comXOMA Jun 2024 20.000 putFebruary 17, 2024 | finance.yahoo.comXOMA Sep 2024 12.500 putFebruary 16, 2024 | markets.businessinsider.comStrategic Acquisitions and Royalty Income Streams Justify Buy Rating for XomaFebruary 16, 2024 | marketwatch.comKinnate Biopharma Shares Rise on XOMA AcquisitionFebruary 16, 2024 | markets.businessinsider.comKinnate Biopharma To Be Acquired By XOMA In Cash Deal; Stock GainsJanuary 18, 2024 | finanznachrichten.deXOMA Corporation: XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA AcquisitionJanuary 18, 2024 | finance.yahoo.comXOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionJanuary 18, 2024 | finance.yahoo.comXOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionJanuary 8, 2024 | marketwatch.comXOMA Names Hughes Permanent CEO; Wyszomierski Becomes ChairmanJanuary 8, 2024 | finance.yahoo.comXOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsDecember 22, 2023 | benzinga.comXOMA Stock (NASDAQ:XOMA) Dividends: History, Yield and DatesNovember 11, 2023 | morningstar.comXOMA Corp XOMANovember 7, 2023 | msn.comXOMA GAAP EPS of -$0.60 misses by $0.12, revenue of $0.83M misses by $0.36MOctober 27, 2023 | finanznachrichten.deObsEva SA: Organon Returns Ebopiprant to XOMAOctober 27, 2023 | finance.yahoo.comOrganon Returns Ebopiprant to XOMASeptember 18, 2023 | msn.comXoma (XOMA) Moves 7.7% Higher: Will This Strength Last?September 15, 2023 | money.usnews.comXOMA CorpSee More Headlines Receive XOMAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 4/15 Dividend4/02/2024Dividend Payable4/15/2024Today5/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:XOMAP CUSIPN/A CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$5.81 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Owen P. Hughes Jr. (Age 49)CEO & Director Comp: $193.75kMr. Thomas M. Burns (Age 50)Senior VP of Finance & CFO Comp: $759.24kMr. Brad Sitko (Age 43)Chief Investment Officer Comp: $867.08kKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors XOMAP Stock Analysis - Frequently Asked Questions How have XOMAP shares performed in 2024? XOMA's stock was trading at $25.41 at the beginning of 2024. Since then, XOMAP stock has decreased by 1.5% and is now trading at $25.02. View the best growth stocks for 2024 here. How often does XOMA pay dividends? What is the dividend yield for XOMA? XOMA announced a quarterly dividend on Wednesday, February 21st. Shareholders of record on Wednesday, April 3rd will be paid a dividend of $0.5391 per share on Monday, April 15th. This represents a $2.16 annualized dividend and a dividend yield of 8.62%. The ex-dividend date of this dividend is Tuesday, April 2nd. Read our dividend analysis for XOMAP. Is XOMA a good dividend stock? XOMA (NASDAQ:XOMAP) pays an annual dividend of $2.16 per share and currently has a dividend yield of 9.29%. XOMAP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for XOMAP. How do I buy shares of XOMA? Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XOMAP) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsNext President (Not Trump. Not Biden.)The Freeport Society4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
